Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer.
Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer.
复制标题
DOI：
10.3892/or_00000263
复制
发表时间：
2009-03
期刊：
影响因子：
4.2
通讯作者：
Xia Zhang;T. Tsukamoto;T. Mizoshita;H. Ban;Hidenori Suzuki;T. Toyoda;M. Tatematsu
中科院分区：
文献类型：
--
作者：
Xia Zhang;T. Tsukamoto;T. Mizoshita;H. Ban;Hidenori Suzuki;T. Toyoda;M. Tatematsu
我们研究了骨桥蛋白（OPN）和CDX2在晚期胃癌中的表达，并分析了其与临床病理特征的相关性，以评估其预后潜力。109名胃癌患者被招募。免疫组化法检测OPN、CDX2等分子标志物的表达。OPN的总阳性率为46.8%，与肿瘤浸润深度和肠道标志物下调有关（P<0.001），而与年龄、性别、组织学类型无关。OPN在cdx2阴性病变中的表达频率（39/109=35.7%）高于cdx2阳性病变（12/109=11.0%），二者呈显著负相关（P<0.001）。OPN阳性肿瘤患者的5年生存率低于OPN阴性肿瘤患者（P<0.001）。进一步分析显示，OPN-/CDX2+组的5年生存率高于其他三组：OPN+/CDX2-、OPN-/CDX2-和OPN+/CDX2+。对5年生存率进行多因素分析，OPN是晚期胃癌预后不良的最显著预测因子（P=0.0043），肿瘤浸润深度是另一个独立指标（P=0.0315）。骨桥蛋白是一种有用的胃癌预后标志物，与CDX2联合使用，在预测晚期胃癌患者的生存方面可能具有特别的优势。此外，本研究结果还提示CDX2可能是胃癌中调节骨桥蛋白表达的转录因子。
We have investigated the expression of osteopontin (OPN) and CDX2 in advanced gastric cancers, and analyzed correlations with clinicopathological features to assess their prognostic potential. One-hundred and nine patients suffering from gastric cancer were recruited. Expression of OPN and CDX2 and other molecular markers was determined by immunohistochemistry. The total positive rate for OPN expression was 46.8%, with a relation to depth of cancer invasion and down regulation of intestinal markers (P<0.001), but not age, gender, or histological type. OPN was more frequently expressed in CDX2-negative (39/109=35.7%) as compared with positive lesions (12/109=11.0%) and a significant reverse correlation was noted between the two factors (P<0.001). Patients with positive OPN tumors had worse 5-year survival than those with OPN-negative cancer (P<0.001). Further analysis revealed the OPN-/CDX2+ group to have better 5-year survival than all the other three groups: OPN+/CDX2-, OPN-/CDX2- and OPN+/CDX2+. With multivariate analysis for 5-year survival, OPN was the most significant predictor of a poor prognosis of advanced gastric cancer (P=0.0043), with tumor depth of invasion as another independent indicator (P=0.0315). Osteopontin is a useful prognostic marker in gastric cancer, and combined with CDX2, may have particular advantage for predicting survival of advanced gastric cancer patients. Furthermore the present results provide a clue that in gastric cancer, CDX2 may be a transcription factor modulating the expression of osteopontin.